EI
DNLI icon

Ellevest Inc’s Denali Therapeutics DNLI Stock Holding History

Ellevest Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-119
Closed -$3.31K – 1938
2022
Q4 		$3.31K Buy
+119
New +$3.54K ﹤0.01% 1284
2022
Q2 		– Sell
-3
Closed – – 1455
2022
Q1 		$0 Sell
3
-8
-73% -$275 ﹤0.01% 1467
2021
Q4 		$0 Sell
11
-4
-27% -$190 ﹤0.01% 1469
2021
Q3 		$1K Sell
15
-14
-48% -$789 ﹤0.01% 1250
2021
Q2 		$2K Sell
29
-3
-9% -$186 ﹤0.01% 1026
2021
Q1 		$2K Buy
32
+5
+19% +$335 ﹤0.01% 1047
2020
Q4 		$2K Buy
27
+16
+145% +$967 ﹤0.01% 961
2020
Q3 		$0 Buy
+11
New +$331 ﹤0.01% 1169
2020
Q2 		– Sell
-33
Closed -$1K – 1171
2020
Q1 		$1K Hold
33
– – ﹤0.01% 866
2019
Q4 		$1K Buy
+33
New +$549 ﹤0.01% 756

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Ellevest Inc's DNLI Position: Q1 2023 in Review

Ellevest Inc sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 119 shares — an estimated $3.31K sold.

Ellevest Inc first reported a position in DNLI in Q4 2019 and held it in 10 quarters. The position peaked at $3.31K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Ellevest Inc reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ellevest Inc sold 119 Denali Therapeutics shares in Q1 2023, an estimated $3.31K.
  • Ellevest Inc first reported a position in Denali Therapeutics in Q4 2019 and held it in 10 quarters.
  • Ellevest Inc's Denali Therapeutics position peaked at $3.31K in Q4 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.